A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China - CNBC

A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China    CNBC Lung Cancer Patients on Drug From China’s Akeso Lived Longer    Bloomberg.com ASCO: Akeso’s ivonescimab bests PD-1 inhibitor in lung cancer chemo combos, slashing death risk by 34%    Fierce Pharma Akeso and Summit’s ivonescimab extends survival in squamous cell lung cancer    statnews.com Summit’s PD-1/VEGF to take center stage at ASCO, with wide impact for peers    BioSpace

Original source: Google News